Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|
| Turnover | --3.17B | 23.28%5.13B | 224.25%736.96M | 26.48%4.16B | --227.28M | 119.45%3.29B | --1.5B |
| Operating income | 3.17B | 23.28%5.13B | 224.25%736.96M | 26.48%4.16B | 227.28M | 119.45%3.29B | 1.5B |
| Cost of sales | ---2.6B | -10.84%-4.38B | -177.69%-668.74M | -10.41%-3.95B | ---240.83M | -143.72%-3.58B | ---1.47B |
| Operating expenses | -2.6B | -10.84%-4.38B | -177.69%-668.74M | -10.41%-3.95B | -240.83M | -143.72%-3.58B | -1.47B |
| Gross profit | 568.68M | 258.98%748.44M | 603.79%68.23M | 171.82%208.49M | -13.54M | -1,061.89%-290.28M | 30.18M |
| Selling expenses | ---16.4M | 37.92%-35.77M | 8.72%-8.46M | -191.31%-57.62M | ---9.27M | -53.95%-19.78M | ---12.85M |
| Administrative expenses | ---172.72M | -16.18%-301.46M | -27.18%-67.85M | -7.61%-259.47M | ---53.35M | -78.95%-241.12M | ---134.74M |
| Research and development expenses | ---252.86M | -31.14%-556.17M | -35.42%-129.14M | -28.80%-424.1M | ---95.37M | -48.96%-329.28M | ---221.05M |
| Impairment and provision | ---5.18M | 10.45%-9.71M | 1,429.33%5.48M | 98.19%-10.84M | --358K | -2,572.03%-600.06M | ---22.46M |
| -Other impairment is provision | ---5.18M | 10.45%-9.71M | 1,429.33%5.48M | 98.19%-10.84M | --358K | -2,572.03%-600.06M | ---22.46M |
| Special items of operating profit | ---64K | 69.21%63.79M | -17.29%12.63M | 117.25%37.7M | --15.27M | -1,224.74%-218.57M | --19.43M |
| Operating profit | 121.45M | 82.04%-90.87M | 23.59%-119.13M | 70.23%-505.83M | -155.91M | -397.56%-1.7B | -341.48M |
| Financing cost | ---68.22M | -80.51%-132.59M | -134.09%-31.46M | -123.31%-73.45M | ---13.44M | 53.16%-32.89M | ---70.22M |
| Share of profit from joint venture company | --160.25M | 1,305.45%302.5M | 4,366.13%77.22M | -2,818.74%-25.09M | ---1.81M | --923K | ---- |
| Earning before tax | 213.48M | 113.08%79.04M | 57.13%-73.37M | 65.09%-604.38M | -171.16M | -320.47%-1.73B | -411.7M |
| Tax | --6.95M | -17.51%11.97M | -4.38%3.47M | 31.13%14.51M | --3.63M | 17.47%11.07M | --9.42M |
| After-tax profit from continuing operations | 220.43M | 115.43%91.01M | 58.28%-69.9M | 65.71%-589.87M | -167.53M | -327.56%-1.72B | -402.28M |
| Earning after tax | 220.43M | 115.43%91.01M | 58.28%-69.9M | 65.71%-589.87M | -167.53M | -327.56%-1.72B | -402.28M |
| Profit attributable to shareholders | 220.43M | 115.43%91.01M | 58.28%-69.9M | 65.71%-589.87M | -167.53M | -327.56%-1.72B | -402.28M |
| Basic earnings per share | 0.09 | 112.90%0.04 | 66.67%-0.03 | 69.31%-0.31 | -0.09 | -288.46%-1.01 | -0.26 |
| Diluted earnings per share | 0.09 | 112.90%0.04 | 66.67%-0.03 | 69.31%-0.31 | -0.09 | -288.46%-1.01 | -0.26 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
| Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young Accounting Firm |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.